Hepatocellular carcinoma (HCC) is one of those Step questions where you either see the pattern instantly… or you drown in lab values and liver buzzwords. The “5-second rule” approach is about recognizing HCC fast from a few high-yield clues: who gets it, what it secretes, what it looks like, and what it does.
The 5-Second Rule (HCC)
If you see cirrhosis + a liver mass + elevated AFP, think:
Hepatocellular carcinoma — primary liver cancer arising in chronically inflamed/cirrhotic liver, classically marked by elevated AFP and arterial enhancement on imaging.
One-Liner You Can Memorize
HCC = “Cirrhosis patient with weight loss + RUQ pain + ↑AFP + arterial enhancing liver mass.”
The Visual / Mnemonic Device: “A.F.P. in a C.I.R.C.L.E.”
Picture a CIRCLE (cirrhosis) drawn around a liver, with AFP stamped in the center like a “cancer seal.”
C.I.R.C.L.E. = HCC risk + presentation
- C = Cirrhosis (biggest overall risk factor)
- I = Infection (HBV, HCV)
- R = Risk toxins (aflatoxin)
- C = Clinical: weight loss, RUQ pain, hepatomegaly
- L = Labs: ↑ AFP
- E = Enhancement: arterial enhancement on contrast imaging
If the vignette gives you cirrhosis + cancer symptoms, your brain should auto-fill AFP and arterial enhancement.
High-Yield Risk Factors (USMLE Favorites)
Major etiologies that set up HCC
- Chronic Hepatitis B (HBV)
- Key Step twist: HBV can cause HCC even without cirrhosis (via DNA integration/oncogenic effects)
- Chronic Hepatitis C (HCV)
- Usually via cirrhosis
- Cirrhosis from any cause, especially:
- Alcohol-related liver disease
- NAFLD/NASH (increasingly tested)
High-yield “classic” association
- Aflatoxin (Aspergillus flavus)
- Found in moldy peanuts/grains
- Synergizes with HBV
- Classically associated with p53 mutation
How It Presents (What the Stem Wants You to Notice)
Common board-style clues:
- Constitutional symptoms: weight loss, fatigue, anorexia
- RUQ pain or abdominal fullness
- Hepatomegaly ± worsening ascites
- Signs of decompensated cirrhosis in the background:
- Variceal bleed, jaundice, encephalopathy, ascites
Paraneoplastic clue (sometimes tested)
- Hypoglycemia (tumor glucose consumption/IGF production)
- Erythrocytosis (EPO production) — less common but fair game
The Two Fastest Diagnostic Anchors
1) AFP
- AFP is associated with HCC, but:
- Not perfectly sensitive/specific
- Mild AFP elevations can occur in chronic hepatitis/cirrhosis
- Very high AFP + mass in at-risk patient = strong signal for HCC
2) Imaging pattern: arterial enhancement
HCC lesions are typically arterially supplied, so on contrast imaging they show:
- Arterial phase hyperenhancement
- Often washout in the portal venous/delayed phase
Screening: Who Gets Watched (and How)
Boards love screening because it’s concrete:
High-risk patients (esp. cirrhosis) → ultrasound every 6 months
Often combined with AFP, depending on guideline/setting.
Who counts as high risk?
- All cirrhosis (regardless of cause)
- Many chronic HBV patients even without cirrhosis (risk-stratified by age/ethnicity/family history)
Differentials You Must Not Confuse (Quick Table)
| Condition | Classic setting | Key clue | AFP? |
|---|---|---|---|
| Hepatocellular carcinoma | Cirrhosis, HBV/HCV, aflatoxin | Arterial enhancement, systemic symptoms | ↑ AFP (often) |
| Cholangiocarcinoma | PSC, liver flukes (SE Asia), biliary disease | Obstructive jaundice, biliary strictures | Usually not AFP |
| Metastatic liver lesions | Known primary cancer (colon, breast, lung) | Multiple lesions common | No AFP pattern |
| Hepatic hemangioma | Incidental | Peripheral nodular enhancement | No |
Step pro-tip: If they say PSC + UC and a biliary tree issue → think cholangiocarcinoma, not HCC.
The 5-Second Exam Script (Say This in Your Head)
- Does the patient have cirrhosis or viral hepatitis?
- Do they have RUQ pain/weight loss/decompensation?
- Is AFP elevated?
- Does imaging show arterial enhancement (± washout)?
→ HCC.
Ultra-High-Yield Takeaways (What You Want on Test Day)
- #1 risk factor: cirrhosis (any cause)
- HBV can cause HCC without cirrhosis
- Aflatoxin (moldy grains/peanuts) → p53
- Marker: AFP
- Imaging: arterial phase enhancement (often with washout)
- Screen high-risk patients: ultrasound q6 months